Global Neuroprotection Market Insights, Forecast to 2025

Table of Contents

1 Study Coverage

• 1.1 Neuroprotection Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Neuroprotection Market Size Growth Rate by Product
  • 1.4.2 Free Radical Trapping Agents (Antioxidants)
  • 1.4.3 Glutamate Antagonists (Anti-Excitotoxic Agents)
  • 1.4.4 Apoptosis Inhibitors
  • 1.4.5 Anti-inflammatory Agents
  • 1.4.6 Neurotrophic Factors (NTFs)
  • 1.4.7 Metal Ion Chelators
  • 1.4.8 Stimulants
  • 1.4.9 Others
• 1.5 Market by End User
  • 1.5.1 Global Neuroprotection Market Size Growth Rate by End User
  • 1.5.2 Prevention
  • 1.5.3 Treatment
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Neuroprotection Market Size
  • 2.1.1 Global Neuroprotection Revenue 2014-2025
  • 2.1.2 Global Neuroprotection Sales 2014-2025
• 2.2 Neuroprotection Growth Rate by Regions
  • 2.2.1 Global Neuroprotection Sales by Regions
  • 2.2.2 Global Neuroprotection Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Neuroprotection Sales by Manufacturers
  • 3.1.1 Neuroprotection Sales by Manufacturers
  • 3.1.2 Neuroprotection Sales Market Share by Manufacturers
  • 3.1.3 Global Neuroprotection Market Concentration Ratio (CR5 and HHI)
• 3.2 Neuroprotection Revenue by Manufacturers
  • 3.2.1 Neuroprotection Revenue by Manufacturers (2014-2019)
  • 3.2.2 Neuroprotection Revenue Share by Manufacturers (2014-2019)
• 3.3 Neuroprotection Price by Manufacturers
• 3.4 Neuroprotection Manufacturing Base Distribution, Product Types
  • 3.4.1 Neuroprotection Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Neuroprotection Product Type
  • 3.4.3 Date of International Manufacturers Enter into Neuroprotection Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Neuroprotection Sales by Product
• 4.2 Global Neuroprotection Revenue by Product
• 4.3 Neuroprotection Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Neuroprotection Breakdown Data by End User

6 North America

• 6.1 North America Neuroprotection by Countries
  • 6.1.1 North America Neuroprotection Sales by Countries
  • 6.1.2 North America Neuroprotection Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Neuroprotection by Product
• 6.3 North America Neuroprotection by End User

7 Europe

• 7.1 Europe Neuroprotection by Countries
  • 7.1.1 Europe Neuroprotection Sales by Countries
  • 7.1.2 Europe Neuroprotection Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Neuroprotection by Product
• 7.3 Europe Neuroprotection by End User

8 Asia Pacific

• 8.1 Asia Pacific Neuroprotection by Countries
  • 8.1.1 Asia Pacific Neuroprotection Sales by Countries
  • 8.1.2 Asia Pacific Neuroprotection Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Neuroprotection by Product
• 8.3 Asia Pacific Neuroprotection by End User

9 Central & South America

• 9.1 Central & South America Neuroprotection by Countries
  • 9.1.1 Central & South America Neuroprotection Sales by Countries
  • 9.1.2 Central & South America Neuroprotection Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Neuroprotection by Product
• 9.3 Central & South America Neuroprotection by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Neuroprotection by Countries
  • 10.1.1 Middle East and Africa Neuroprotection Sales by Countries
  • 10.1.2 Middle East and Africa Neuroprotection Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Neuroprotection by Product
• 10.3 Middle East and Africa Neuroprotection by End User

11 Company Profiles

• 11.1 Daiichi Sankyo Company
  • 11.1.1 Daiichi Sankyo Company Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Daiichi Sankyo Company Neuroprotection Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Daiichi Sankyo Company Neuroprotection Products Offered
  • 11.1.5 Daiichi Sankyo Company Recent Development
• 11.2 Eli Lilly and Company
  • 11.2.1 Eli Lilly and Company Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Eli Lilly and Company Neuroprotection Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Eli Lilly and Company Neuroprotection Products Offered
  • 11.2.5 Eli Lilly and Company Recent Development
• 11.3 Allergan
  • 11.3.1 Allergan Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Allergan Neuroprotection Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Allergan Neuroprotection Products Offered
  • 11.3.5 Allergan Recent Development
• 11.4 Dr. Reddy’s Laboratories
  • 11.4.1 Dr. Reddy’s Laboratories Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Dr. Reddy’s Laboratories Neuroprotection Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Dr. Reddy’s Laboratories Neuroprotection Products Offered
  • 11.4.5 Dr. Reddy’s Laboratories Recent Development
• 11.5 Teva Pharmaceutical
  • 11.5.1 Teva Pharmaceutical Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Teva Pharmaceutical Neuroprotection Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Teva Pharmaceutical Neuroprotection Products Offered
  • 11.5.5 Teva Pharmaceutical Recent Development
• 11.6 Novartis
  • 11.6.1 Novartis Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Novartis Neuroprotection Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Novartis Neuroprotection Products Offered
  • 11.6.5 Novartis Recent Development
• 11.7 AstraZeneca
  • 11.7.1 AstraZeneca Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 AstraZeneca Neuroprotection Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 AstraZeneca Neuroprotection Products Offered
  • 11.7.5 AstraZeneca Recent Development
• 11.8 Astrocyte Pharmaceuticals
  • 11.8.1 Astrocyte Pharmaceuticals Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Astrocyte Pharmaceuticals Neuroprotection Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Astrocyte Pharmaceuticals Neuroprotection Products Offered
  • 11.8.5 Astrocyte Pharmaceuticals Recent Development
• 11.9 F. Hoffmann-La Roche
  • 11.9.1 F. Hoffmann-La Roche Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 F. Hoffmann-La Roche Neuroprotection Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 F. Hoffmann-La Roche Neuroprotection Products Offered
  • 11.9.5 F. Hoffmann-La Roche Recent Development
• 11.10 Biogen
  • 11.10.1 Biogen Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Biogen Neuroprotection Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Biogen Neuroprotection Products Offered
  • 11.10.5 Biogen Recent Development

12 Future Forecast

• 12.1 Neuroprotection Market Forecast by Regions
  • 12.1.1 Global Neuroprotection Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Neuroprotection Revenue Forecast by Regions 2019-2025
• 12.2 Neuroprotection Market Forecast by Product
  • 12.2.1 Global Neuroprotection Sales Forecast by Product 2019-2025
  • 12.2.2 Global Neuroprotection Revenue Forecast by Product 2019-2025
• 12.3 Neuroprotection Market Forecast by End User
• 12.4 North America Neuroprotection Forecast
• 12.5 Europe Neuroprotection Forecast
• 12.6 Asia Pacific Neuroprotection Forecast
• 12.7 Central & South America Neuroprotection Forecast
• 12.8 Middle East and Africa Neuroprotection Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Neuroprotection Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details